Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, MD, President and CEO, will present at the H.C. Wainwright BIOCONNECT Virtual Conference, taking place from January 10 – 13, 2022.

H.C. Wainwright BIOCONNECT Conference
Date: January 10 – 13, 2022
Presentation Time: Available on-demand January 10, 2022 at 7:00 am ET
Webcast: https://journey.ct.events/view/af6d1ca2-50d5-48b4-a5ce-ae85ca68054f
Conference Website: Click here

The presentation can also be accessed from Acorda’s website: https://ir.acorda.com/investors/investor-events/default.aspx

About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA^® is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS^® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA^® (dalfampridine) Extended Release Tablets, 10 mg.